

Semaphorin 3C exacerbates liver fibrosis

Francesca De Angelis Rigotti^{1*}, Lena Wiedmann^{1,2*}, Max Ole Hubert^{1,3}, Margherita Vacca¹, Sana S. Hasan¹, Iris Moll¹, Silvia Carvajal⁴, Wladimiro Jiménez⁴, Maja Starostecka^{1,2,5}, Adrian T Billeter⁶, Beat Müller-Stich⁶, Gretchen Wolff^{7,8,9}, Bilgen Ekim-Üstünel^{7,8,9}, Stephan Herzig^{7,8,9}, Carolin Mogler¹⁰, Andreas Fischer^{1,3,11*}, Juan Rodriguez-Vita^{1*}

¹Division Vascular Signaling and Cancer, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.

²Faculty of Biosciences, University of Heidelberg, 69120 Heidelberg, Germany.

³European Center for Angioscience (ECAS), Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany.

⁴Service of Biochemistry and Molecular Genetics, Hospital Clinic Universitari, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

⁵Current address: European Molecular Biology Laboratory (EMBL), Genome Biology Unit, 69126 Heidelberg, Germany

⁶Department of General, Visceral and Transplantation Surgery, University of Heidelberg Hospital, 69120 Heidelberg, Germany.

⁷Institute for Diabetes and Cancer (IDC), Helmholtz Diabetes Center, Helmholtz Centre Munich, Neuherberg, Germany.

⁸Joint Heidelberg-IDC Translational Diabetes Program, Department of Internal Medicine 1, Heidelberg University Hospital, Heidelberg, Germany.

⁹German Center for Diabetes Research (DZD), Neuherberg, Germany, and Chair Molecular Metabolic Control, Technical University Munich, Munich, Germany.

¹⁰Institute of Pathology, Technical University of Munich, 81675 Munich, Germany.

¹¹Department of Medicine 1 and Clinical Chemistry, University Hospital of Heidelberg, 69120 Heidelberg, Germany.

* These authors contributed equally to this work.

Correspondence to: a.fischer@dkfz.de and j.rodriguezvita@dkfz.de

Abstract

Background: Chronic liver disease is a growing epidemic leading to fibrosis and cirrhosis. TGF- β is the pivotal pro-fibrogenic cytokine which activates hepatic stellate cells (HSC), yet, other molecules can substantially modulate TGF- β signalling in the course of liver fibrosis. Expression of the axon guidance molecules Semaphorins (SEMA3s), which signal through Plexins and Neuropilins (NRPs), have been associated with liver fibrosis in HBV-induced chronic hepatitis. However, their function in the regulation of HSCs has not yet been described.

Results: SEMA3C is the most enriched member of the Semaphorin family in liver samples from cirrhotic patients. Higher expression of SEMA3C in patients with NASH, alcoholic hepatitis or HBV-induced hepatitis discriminates those with a more pro-fibrotic transcriptomic profile. SEMA3C expression is also elevated in different mouse models of liver fibrosis and in isolated HSCs upon activation. In keeping with this, deletion of SEMA3C in activated HSCs reduces myofibroblast marker expression. Conversely, SEMA3C overexpression exacerbates TGF- β -mediated myofibroblast activation, as shown by increased SMAD2/3 phosphorylation and target gene expression. Among SEMA3C receptors, only NRP2 expression is maintained upon activation of isolated HSCs. Interestingly, lack of NRP2 in those cells reduces myofibroblast marker expression. Finally, deletion of either SEMA3C or NRP2, specifically in activated HSCs, reduces liver fibrosis in mice.

Conclusion: SEMA3C is a novel marker for activated HSCs that plays a fundamental role in the acquisition of the myofibroblastic phenotype and liver fibrosis.

Introduction

Chronic liver disease (CLD) is a global epidemic that affects more than 850 million people [1]. The cause of CLD can be attributed to different origins, most importantly hepatitis virus C and B, alcohol consumption and metabolic disorders leading to non-alcoholic steatohepatitis (NASH)[1]. CLD is a complex disorder with different cell types contributing in multiple ways to its progression[2]. However, no matter the cause for CLD, all aetiologies have in common that hepatic stellate cells (HSCs) get activated. These produce aberrant extracellular matrix (ECM), accumulating in the extracellular space, generating a scar[3] and eventually impairing liver function[4]. Understanding how HSCs get activated could help design better therapies to ameliorate the consequences of CLD.

It is well known that TGF- β is the main driver for the activation of HSCs[4]. TGF- β signals through its receptor complex to activate mainly SMAD2/3 transcription factors[5]. The TGF- β receptor complex is composed of the different TGF- β receptors, type I and II, and can include co-receptors like Neuropilin-1 (NRP1) or NRP2. NRPs exert no signalling function on their own, but modulate the signalling machinery[6–8]. These co-receptors can also be recognised by other signalling molecules, such as distinct semaphorin proteins, suggesting that these may alter TGF- β signalling.

The semaphorin family of proteins (SEMA) were initially described to be involved in axon guidance during development[9], however, these proteins contribute to several other cell functions[10]. Interestingly, SEMA7A potentiates TGF- β -induced pulmonary fibrosis[11], suggesting that SEMAs could have a role in fibrosis in other organs. The class III semaphorin (SEMA3) subfamily is the only group of semaphorins that is secreted[12]. Some of SEMA3 members have been reported to be involved in the regulation of fibrosis. SEMA3A activates retinal fibroblasts, inducing differentiation into myofibroblast[13], while SEMA3E mediates HSC activation in a model of acute liver injury[14]. SEMA3C expression correlates with liver cirrhosis[15], whether it plays a functional role in this process is however not known. Intriguingly, SEMA3C signals mainly through its interaction with PlexinD1, NRP1 and NRP2[16]. While NRP1 plays an essential role in liver fibrosis[17,18], the role of NRP2 in liver fibrosis is unknown. Here we show that SEMA3C potentiates TGF- β signalling and exacerbates myofibroblast trans-differentiation induced by TGF- β and that this is, at least in part, mediated by NRP2.

Materials and Methods

Patient samples

Liver biopsies were collected from patients undergoing bariatric surgery at the University Hospital of Heidelberg. Collection was approved by the Institutional Review Board of the Medical Faculty of the University of Heidelberg in accordance with the Declaration of Helsinki. All patients gave preoperative consent.

Mouse models

All animal experiments were approved by and performed in accordance with the institutional and regional Animal Welfare Committee. Animals were housed in groups in pathogen-free conditions. SM22 α ^{CRE}/SEMA3C^{fl/fl} or NRP2^{fl/fl} constitutive knockout mice were obtained by crossing SM22 α ^{CRE} mice with either SEMA3C^{fl/fl} or NRP2^{fl/fl} mice to achieve the specific deletion of *Sema3C* or *Nrp2* genes only in cells expressing SM22 α . These mice did not show any evident burden attributable to their genetic background at the ages at which the experiments were carried out. A constitutive knockout was chosen to fit to the continuous character of the disease, resulting in a knockout of SEMA3C or NRP2 in all activated HSCs independent of when their activation happened. Since SM22 α is expressed in cardiomyocytes and both, SEMA3C and NRP2 play important roles in cardiac function and development [19,20], mice had to be euthanized before reaching 25 weeks of age according to Animal Welfare Committee regulations. This decision was also based on the findings that 30 weeks old SM22 α ^{CRE}/NRP1^{fl/fl} mice develop heart failure [21]. For genotyping, the following primers were used: SM22 α ^{CRE} fw: GCGGTCTGGCAGTAAAACTATC, rev: GTGAAACAGCATTGCTGCTCACTT; SEMA3C flox fw: GAATCTGGCAAAGGACGATG, rev: GACCACTGGGCTTGAGAGAG; NRP2 flox common fw: AGCTTTTGCCTCAGGACCCA, NRP2 flox mutant rev: CCTGACTACTCCCAGTCATAG NRP2 Wildtype rev: CAGGTGACTGGGGATAGGGTA. Experiments started between 8-12 weeks of age on male mice. All mice were obtained from in-house breeding.

For CCl₄ treatment, mice were kept on standard chow and injected 3x weekly with 0,5 mg/kg CCl₄ (VWR International, Cat. No. SIAL289116) diluted 1:5 in olive oil (Carl Roth, Cat. No. 8873.1) for 2, 4 or 6 weeks.

For high-fat diet (HFD) experiments, wild type C57BL/6N mice were kept on a diet containing 60% fat, 20% carbohydrate, 20% proteins (Research Diets, Cat. No. D12492i) for 13 weeks from the age of 8 weeks. Control mice received standard chow.

For the FPC diet, wild type C57BL/6N mice were fed for 24 weeks with Fructose-Palmitate-Cholesterol high fat diet (Research Diets, Cat. No. D17020104i), while littermate controls were kept on control diet (Research Diets, Cat. No. D17020105i).

Cells

GRX, a cell line of activated HSCs derived from a mouse model of schistosomiasis[22], and primary hepatic stellate cells (HSCs) were used in this work. Cells were cultured in DMEM GlutaMax (Thermo Fisher Scientific, Cat. No. 21885025) supplemented with 10 % FCS and 1 % Pen/Strep. For the experiments with TGF- β , GRX cells were maintained in starvation (medium without FCS) for 48 h before stimulation and during all the duration of the experiment. Stimulation with TGF- β (10 ng/ml, Bio-Techne, Cat. No. 240-B-010/CF) was performed for 15 minutes, 3 or 24 hours.

HSC isolation

Isolation of primary murine hepatic stellate cells (HSCs) was performed as previously described with individual modifications[23]. In short: After cervical dislocation and immediate median laparotomy, the inferior vena cava (IVC) was exposed and then liver perfusion was performed via the IVC for 2 minutes with EGTA buffer[23], for 5 minutes with pronase (MERCK, cat. no. 10165921001) and for 5 minutes with liberase (MERCK, cat. no. 5401127001). Afterwards, the liver capsule was carefully removed and the liver was minced. The minced liver was resuspended in GBBS/B[23] and then washed twice. HSCs were separated from other parenchymal and non-parenchymal liver cells by density gradient centrifugation, using Histodenz (MERCK, cat. no. D2158-100G) for layering. HSCs were collected from the interphase between the two layers and then plated in 10% FCS, 1% PenStrep DMEM. For 0-9 days activation experiments, a fraction of HSCs was lysed and RNA was isolated immediately after HSC collection. Remaining HSCs were cultured for 9 days and then lysed for RNA isolation.

Lentiviral overexpression

Sema3C cDNA (NCBI DQ890847) vector from Genomic and Proteomics Core Facility of German Cancer Research Center was shuttled into pLenti6.2/V5-DEST (Invitrogen) by Gateway cloning for virus production. Sema3C or empty plasmids were transfected with plasmids for envelope (pMD2.G plasmid coding for VSV-G) and packaging (psPAX2) of lentiviral particles into HEK293T cells for virus production. Supernatant of these HEK293T cells was harvested 48

and 72h after transfection and virus was enriched by ultracentrifugation. Stable cell lines were generated by infection of GRX cells with viral particles and subsequent selection with blasticidin.

Immunohistochemistry

Livers of mice were harvested and fixed in ROTI®Histofix 4 % (Carl Roth GmbH, Cat. No. P087.3) over night at 4°C before paraffin embedding. Stainings were performed on deparaffined cuts of 3µm.

Sirius Red staining was performed according to manufacturer's protocol (Picro-Sirius Red Stain Kit, Dianova, Cat. No. PSR-1).

For SEMA3C (Bio-Techne, Cat. No. AF1728, 1:50), DESMIN (Abcam, Cat. No. ab15200, 1:100) and SM22α (abcam, Cat. No. ab137453, 1:100) stainings, antigen retrieval was performed at pH=6. After 3 fast washes in permeabilization buffer (TBS-0,025% Triton-X100), tissues were incubated for 30 minutes in Animal free Blocking solution (Cell Signaling 15019S, 1:5) and then with primary antibodies at 4°C ON. Endogenous peroxidase activity was inhibited by H₂O₂ treatment before adding Goat IgG VisUCyte HRP Polymer (R&D Systems, Cat. No. VC004 Substrate: DAB Substrate Kit, Zytomed, Cat. No. DAB057) for 30 minutes. For double staining, samples were subsequently incubated for 30 minutes with ZytoChem Plus (AP) Polymer anti-Rabbit (Biozol Diagnostica, Cat. No. ZYT-ZUC031-00, Substrate: Permanent AP-Red-Kit, Zytomed, Cat. No. ZUC001-125). Tissue was counterstained with hematoxylin/eosin for 3 seconds before dehydration and embedding in mounting medium (Eukitt, Cat. No. 202200401).

For immunofluorescence of αSMA, antigen retrieval was performed at pH=9. After 3 fast washes in permeabilization buffer (TBS-0,025% Triton-X100), samples were incubated for 30 minutes in 10% goat-serum, (Cell Signaling 15019S, 1:5) and then with diluted anti-αSMA-Cy3 antibody (Sigma Aldrich, Cat. No. C6198, 1:200) for 1h at RT. After washes, tissue was dehydrated and mounted with fluorescence mounting medium (Dako, Cat. No. S3023).

Pictures were acquired using the Zeiss Axio Scan.Z1 and analyzed with the Fiji Software.

Immunocytochemistry

For immunofluorescence staining of αSMA, GRX cells were seeded onto coverslips, starved ON and stimulated with 10 ng/ml TGF-β (Bio-Techne, Cat. No. 240-B-010/CF) for 24 h. Cells were fixed and permeabilized using cold MeOH for 3 min on ice. After blocking, cells were incubated with αSMA antibody (Sigma, Cat. No. A5228, 1:500) for 2 hours at room temperature. Donkey anti-mouse IgG Alexa Fluor 546 antibody (Invitrogen, Cat. No. A10036) was incubated for 1 h the next day prior to DAPI staining. Coverslips were mounted on slides with fluorescence mounting medium (Dako, Cat. No. S3023). Images were acquired using Zeiss Axio Scan.Z1.

mRNA isolation and qRT-PCR

For qRT-PCR analysis, mRNA of GRX cells was isolated with the innuPREP RNA Mini Kit (Analytik Jena AG, Cat. No. 845-KS-20400250) according to manufacturer's protocol. For HSCs, the ARCTURUS® PicoPure® RNA Isolation Kit (Thermo Fisher Scientific, Cat. No. KIT0214) was used. The extraction of mRNA from snap-frozen tissue was performed using Trizol® reagent (Thermo Fisher Scientific, Cat. No. 15596026) and precipitation with isopropanol. Retrotranscription of mRNA was carried out using the Reverse Transcriptase Kit (Applied Biosciences, Cat. No. 4368814). qRT-PCR was performed using SybrGreen Master Mix (Applied Biosciences, Cat. No. A25742) and the following primers. Fold changes were assessed by $2^{-\Delta\Delta C_t}$ method and normalized with the gene *Cph* or *Hprt*.

| Gene | Forward Primer | Reverse Primer |
|-------------------------------|---------------------------|----------------------------|
| <i>Acta2</i> | GAGAAGCCCAGCCAGTCG | CTCTTGCTCTGGGCTTCA |
| <i>Col1a2</i> | GTAAC TTCGTGCCTAGCAACA | CCTTTGTCAGAATACTGAGCAGC |
| <i>Cph</i> | ATGGTCAACCCACCGTG | TTCTTGCTGTCTTTGGAAC TTTGTC |
| <i>Ctgf</i> | CTTCTGCGATTTGGCTCC | TACACCGACCCACCGAAGA |
| <i>Hprt</i> | TGACACTGGCAAACAATGCA | GGTCCTTTTCACCAGCAAGCT |
| <i>Mmp12</i> | CTCATGATGATTGTGTTCTTACAGG | GACAAGTACCATT CAGCAAATTCAC |
| <i>Nrp1</i> | GTCTTCAGGGCCCTTTCTCT | ATGTAGGTGCACTCCAAGCT |
| <i>Nrp2</i> | GCTGGCTACATCACTTCCCC | CAATCCACTCACAGTTCTGGTG |
| <i>Pai-1</i> | TCGTGGAAC TGCCTACCAG | ATGTTGGTGAGGGCGGAGAG |
| <i>PlexinD1</i> | GACTCGAAC TTTCTTCCCCA | CAGTGAGGAGAACAGGCTGA |
| <i>S100a6</i> | AAGCTGCAGGATGCTGAAAT | CCCTTGAGGGCTTCATTGTA |
| <i>Sema3C</i> | TGGCCACTCTTGCTCTAGGT | AGATGCCTGTGGAGACTTGG |
| <i>Tagln</i> (SM22 α) | TCCAGTCCACAAACGACCAAGC | GAATTGAGCCACCTGTTCCATCT |

Western Blot

Western blot was performed as previously described. In short, cultured cells were lysed with Cell Lysis Buffer (Cell Signalling, Cat. NO. 9803S) supplemented with 2% PMSF (50mM in EtOH). For snap-frozen livers, tissue was homogenized in RIPA buffer (25mM Tris pH 7,4, 150mM NaCl, 1% NP40, 1% Sodium Deoxycholate, 0,1% SDS) supplemented with 2% PMSF (50mM in EtOH). Proteins separated via SDS-PAGE gels were blotted onto PVDF membranes (Millipore, Cat. No. ISEQ00010) To reduce non-specific antibody binding and reduce background, blocking- and antibody-incubations were performed in TBS + 0,1% Tween20 + 5% milk. Following primary antibodies were used: anti-NRP1 (1:1000, R&D Systems, Cat. No. AF566), anti-NRP2 (1:1000, R&D Systems, Cat. No. AF567), anti-VCP (1:2000, abcam, Cat. No. ab109240), anti-pSMAD2/3 (1:1000, Cell Signaling, Cat. No. 8828), anti-SM22 α (1:1000, abcam, Cat. No. ab137453), anti-FN1 (1:1000, abcam, Cat. No. ab2413). After washes, appropriate HRP-coupled secondary antibodies (rabbit anti-mouse, Cat. No. P0260, and goat anti-rabbit, Cat. No. P0448, from DAKO and rabbit anti-goat, Cat. No. HAF017, from R&D

Systems) were used with a dilution 1:2500. Already HRP-conjugated rabbit anti-mouse (Dako, Cat. No. P0260) was also used to recognize heavy-chain immunoglobulins (hc-Ig) present in liver lysates. SuperSignal™ West Pico PLUS Chemiluminescent Substrate (Thermo Fisher Scientific, Cat. No. 34579) was used to detect HRP.

Gene set enrichment analysis (GSEA)

Gene Set Enrichment Analysis (GSEA, Broad Institute)[24] was used to examine differentially expressed genes (DEGs). The output of GSEA is an enrichment plot (ES), a normalized enrichment score (NES) which accounts for the size of the gene set being tested, a p-value, and an estimated False Discovery rate (FDR). We computed p-values using 1,000 permutations for each gene set and corrected them with the false-discovery rate (FDR) method. When several probe sets were present for a gene, the mean of the probe set was used. We used publicly available data sets of liver fibrosis patients (NCBI GEO GSE45050, GSE61260, GSE103580, GSE83898) for the analysis.

Statistical analysis

Data are presented as mean \pm SD, with data points representing different biological replicates. Statistical analysis was performed with GraphPad Prism 9 software. The test used in each experiment is described in the figure legend. In brief, for *in vivo* experiments, the non-parametric Mann-Whitney test was applied. For *in vitro* experiments, Gaussian distribution of data was assumed, so parametric unpaired t-test was performed. For comparing *ex vivo* analysis of HSC activation comparing 0 and 9 days after isolation, paired t-test was carried out. One-tailed analysis was performed when one direction hypothesis was supported by previous experiments. Differences were considered significant, if p-value was ≤ 0.05 . Asterisks were used as followed: * $p \leq 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$.

Results

SEMA3C expression is associated with liver fibrosis in human patient samples

To address relative gene expression patterns of semaphorin family members in human CLD samples, we examined a publicly available database (GSE45050) which provides gene expression profiles from patients with liver cirrhosis (n=5) and healthy donors (n=3). Gene set enrichment analysis (GSEA) comparing healthy versus cirrhotic patients using the GO_SEMAPHORIN_PLEXIN_SIGNALING_PATHWAY gene set revealed that this gene set was enriched upon liver cirrhosis (**Figure 1A**). The most enriched gene in this set was SEMA3C, suggesting that its role could be important in the context of liver cirrhosis. We extracted a list of the 500 most enriched genes in liver cirrhosis from this GSEA and named it “Cirrhosis signature”. Interestingly, three different class 3 semaphorins were among these genes (**Suppl. Table 1**): SEMA3D, SEMA3A, among the top 400, and SEMA3C, which was in the top 100 of most enriched genes. Therefore, we decided to test the association of SEMA3C with fibrosis. We used again publicly available datasets from different cohorts of patients suffering NASH (GSE61260) (**Figure 1B**), alcoholic cirrhosis (GSE103580) (**Figure 1C**) and chronic HBV infection (GSE83898) (**Figure 1D**). We classified the different cohorts of patients based on their SEMA3C expression as over (SEMA3C-high) or under the mean (SEMA3C-low). GSEA of “Cirrhosis signature” showed significant enrichment of this gene set in patients with higher SEMA3C expression in all aetiologies for CLD (**Figure 1B-D**), suggesting its importance in liver fibrosis. To ensure that this was not an unspecific association between SEMA3C and fibrosis, we performed the same classification (over or under the mean) with other Semaphorin genes that have been related to fibrosis in the literature, SEMA3E, SEMA3A, SEMA5A and SEMA7A [11,13-15]. We found that although these genes showed the same trend, SEMA3C had the strongest significant association in all three disorders (**Suppl. Figure 1A**). In summary, these data indicate that SEMA3C expression is associated with a worse mRNA expression profile in patients with liver fibrosis from different aetiologies.

To understand whether this was due to its impact on fibroblast activation, we examined the expression of SEMA3C in liver samples from patients with non-alcoholic fatty liver disease (NAFLD). We found SEMA3C expression in DESMIN positive cells (**Figure 1E**), indicating that SEMA3C was expressed in HSCs. We also analysed the expression of a marker for fibroblast activation, smooth muscle protein 22-alpha (SM22 α). Although, the investigated patient samples exhibited only mild signs of fibrosis (based on clinical pathology reports), they started to show SM22 α positive staining in non-arterial areas (**Figure 1F**). This indicates that fibroblasts, probably HSCs, had been activated already. When analysing SEMA3C expression patterns in

serial sections, we observed that SEMA3C positive areas were in very similar locations as those observed with SM22 α , suggesting that its presence could have a role in HSC activation (**Figure 1F**).

SEMA3C is upregulated in several mouse models for liver fibrosis

We further analysed whether we could observe the same kind of association in mouse models for liver fibrosis. We used two models for NAFLD, i.) high fat diet (HFD) and ii.) fructose, palmitate, cholesterol and trans-fat diet (FPC), and in addition the classical model of CCl₄-induced liver fibrosis. Although all three models showed signs of early fibrosis, only CCl₄-treated mice had advanced liver fibrosis in relatively short time (**Suppl. Figure 2A**). Nonetheless, in all three models we observed a significant increase of SEMA3C upon liver injury (**Figure 2A**). Similar to what we observed in patients with NAFLD, SEMA3C was expressed by DESMIN positive fibroblasts and was more concentrated in fibrotic areas (**Figure 2B**).

SEMA3C is a marker for HSC activation

Thus far, we have been able to correlate SEMA3C expression with liver fibrosis, but we aimed at understanding whether this was functionally relevant. For this reason, HSCs from livers of wild-type C57BL/6 mice were isolated by density gradient and activated by *in vitro* culture (**Suppl. Figure 3A**). *In vitro* culture has been shown to be sufficient to activate HSCs into myofibroblasts[25]. We confirmed this by observing that several markers for activated fibroblasts (*Ctgf*, *Acta2* (α SMA), *Tagln* (SM22 α) and *Pai-1*) were increased upon *in vitro* culture for 9 days (**Suppl. Figure 3B**). When looking at SEMA3C expression we observed a significant increase in activated HSCs (**Figure 3A**), indicating that SEMA3C can be considered as a new marker for activated fibroblasts.

To demonstrate the importance of SEMA3C in HSC activation, we isolated HSCs from SM22 α ^{CRE}/SEMA3C^{fl/fl} and their littermate controls SEMA3C^{fl/fl}. In SM22 α ^{CRE}/SEMA3C^{fl/fl} mice SEMA3C deletion is controlled by SM22 α promoter, whose activity increases upon HSC activation. We observed that, after 9 days of culture, HSCs from CRE-positive mice had a significantly reduced expression of several myofibroblast markers compared to their CRE-negative littermate controls (**Figure 3B**), indicating that SEMA3C expression is necessary for HSC activation.

Further, we overexpressed SEMA3C in GRX cells, a cell line of activated HSCs [22]. We observed that TGF- β -mediated gene expression was exacerbated in those cells overexpressing SEMA3C (**Figure 3C**). In addition, TGF- β -induced SMAD2/3 phosphorylation in SEMA3C-overexpressing GRX was significantly increased compared to control cells (**Figure 3D**). This

was further confirmed by staining for α SMA by immunofluorescence. SEMA3C-overexpressing GRX showed a stronger formation of α SMA⁺ cytoskeletal filaments compared to control cells, which confirms the increased myofibroblast activation of HSCs upon SEMA3C overexpression (**Figure 3E**). All these data indicate that SEMA3C increases TGF- β responses in HSCs and GRX *in vitro*.

SEMA3C exacerbates liver fibrosis in mice

To analyse whether SEMA3C could also mediate fibrosis *in vivo*, we induced liver fibrosis in mice lacking SEMA3C in myofibroblasts. For this, we employed SM22 α ^{CRE}/SEMA3C^{fl/fl} mice. In CRE-positive mice, fibroblasts and all HSCs, which get activated at any phase of liver fibrosis progression, lack SEMA3C (**Figure 4A**). We used CCl₄-injection as liver fibrosis model because, due to the short time this model requires to induce fibrosis, is the most compatible with the chosen mouse strain. Lack of SEMA3C in myofibroblasts led to significant decrease of several liver fibrosis markers, such as *Acta2* or *S100a6* mRNA expression, as well as FN1, SM22 α and α SMA protein expression (**Figure 4B-F**). In addition, immunoglobulin presence in the liver, a marker for liver fibrosis (**Suppl. Figure 2C**)[26] was strongly reduced (**Figure 4E-F**). Taken together, these data demonstrate that SEMA3C exacerbates liver fibrosis.

NRP2 deletion in HSCs reduces liver fibrosis in mice

SEMA3C signals through PlexinD1, NRP1 and NRP2 receptors[27]. Given that NRPs are co-receptors in the TGF- β receptor complex[28] we further determined their contribution to HSC activation and liver fibrosis. When analysing the expression of NRPs upon fibrosis, we observed that NRP1 increased with fibrosis development, as expected from previous literature[17]. Interestingly, we observed a similar upregulation of NRP2, suggesting a previously unknown effect of NRP2 on liver fibrosis (**Figure 5A**). However, when analysing gene expression in primary HSCs activated in culture, we observed that while *Plexnd1* and *Nrp1* were almost abolished in activated HSCs, these conserved *Nrp2* expression (**Figure 5B**). These data suggest that NRP2 could be transducing the signal of SEMA3C in activated HSCs.

To evaluate the relevance of NRP2 in HSC activation, we isolated HSCs from SM22 α ^{CRE}/NRP2^{fl/fl} and their littermate controls NRP2^{fl/fl}. We found several markers for HSC activation significantly reduced in cells lacking NRP2, in particular *Tagln* (SM22 α) and *Acta2* (α SMA) (**Figure 5C**). Thus, we concluded that NRP2 is necessary for HSC activation *in vitro*.

In order to confirm the important role of the co-receptor NRP2 in liver fibrosis, we injected CCl₄ in mice lacking NRP2 only in myofibroblasts (SM22 α ^{CRE}/NRP2^{fl/fl} mice) and their littermate controls to induce liver fibrosis. We observed a lower presence of several liver fibrosis

markers in SM22 α ^{CRE}/NRP2^{fl/fl} mice (**Figure 5D-G**). Therefore, the data suggest that the absence of NRP2 in activated HSCs reduces liver fibrosis.

Discussion

CLD is a multifactorial disorder. Most of the molecular mechanisms underlying liver fibrosis are common among the different liver injuries triggering CLD. Also, most of them start with the transdifferentiation of HSCs into myofibroblasts. Understanding the mechanisms for HSC activation could lead to the discovery of better ways to diagnose and treat patients with CLD. Here we have uncovered a new marker for HSC activation, SEMA3C, which predicts a more advanced stage of the disease. In addition, we demonstrate that SEMA3C has a function in liver fibrosis progression, thereby constituting a potential therapeutic target itself. Moreover, we suggest that its effects are, at least in large parts, mediated by the receptor NRP2.

The so-called Western diet and sedentary lifestyle has enormously increased the rate of people affected by NAFLD, or more accurately described by metabolic dysfunction-associated fatty liver disease (MAFLD) [29]. In addition, excessive alcohol consumption or viral infections contribute to the high rate of CLD, constituting a growing epidemic affecting almost a billion people worldwide[1]. The discovery of safe treatments for CLD could be extremely beneficial. Here we describe a previously unknown role for SEMA3C in the activation of HSCs. We provide data showing that SEMA3C expression precedes other more obvious features of liver fibrosis. This suggests that SEMA3C expression might be employed for early detection of liver fibrosis and for a better classification of patients with risk of developing a more advanced disease before the deterioration of liver function arrives to a non-return point.

TGF- β is one of the main drivers for liver fibrosis. It is an important activator of HSCs, and its inhibition has been shown to block liver fibrosis progression[30]. Unfortunately, TGF- β inhibitors are often too toxic to be administered due to pleiotropic effects in many organs. We found that SEMA3C exacerbates TGF- β responses in HSCs. We show how the overexpression of SEMA3C in GRX, a myofibroblast cell line derived from HSCs, increases TGF- β -induced gene expression and SMAD2/3 phosphorylation. Therefore, early increase of SEMA3C expression in HSCs could provoke an overreaction to TGF- β present in the extracellular compartment, accelerating the development of fibrosis that TGF- β mediates. Conversely, deletion of SEMA3C in HSCs reduced their level of activation *in vitro*. This indicates that SEMA3C is not only a consequence of HSC activation, it is also a driver for their activation itself. Future strategies aiming at blocking SEMA3C activity could be useful to reduce TGF- β responses only in damaged organs, limiting the toxicity by avoiding the inhibition of TGF- β pleiotropic actions.

SEMA3C plays an important role in angiogenesis by inhibiting VEGF responses in endothelial cells (ECs) through NRP1[31]. For this reason, it is important to separate the effects of SEMA3C on ECs from potential effects that SEMA3C could have in fibroblasts. To achieve this, we decided to use SM22 α as a driver for CRE recombinase expression because it allowed us to restrict SEMA3C deletion to activated HSCs and myofibroblasts in general. This promoter is also active in VSMCs, although VSMC do not express SEMA3C under normal conditions[2]. Therefore, it is reasonable to suggest that our transgenic mice would only show an effect in activated fibroblasts. We found that when activated fibroblasts lack SEMA3C the fibrotic process, although it is not abolished, it is significantly reduced.

In an attempt to uncover the receptor involved in SEMA3C actions we first evaluated the expression of the different receptors in liver fibrosis and more specifically in HSCs. We found that only NRP2 was still expressed in activated HSCs. In keeping with this, deletion of NRP2 strongly inhibited HSC activation. Moreover, the deletion of NRP2 exclusively in myofibroblasts in mice was sufficient to reduce fibrosis progression, suggesting that activated HSCs respond to SEMA3C overexpression through NRP2 to mediate liver fibrosis. This discovery opens a new line of research, aiming at NRP2 blockade, which, together with the previously established benefits of NRP1 blockade[17,18], could serve as a therapeutical strategy to reduce liver fibrosis.

Taken together, we demonstrate that SEMA3C exacerbates liver fibrosis. Its expression in HSCs is not only a marker of their activation, comparable to other previously defined, but also a mediator of this activation. Indeed, we demonstrate that HSCs decrease their level of activation upon SEMA3C deletion, opening the possibility to target this secreted protein to diminish liver fibrosis in patients.

Acknowledgements

This work was funded by the Deutsche Forschungsgemeinschaft (DFG) project number 394046768 - SFB1366 projects C4 and Z2 (to A.F., C.M.), DFG project number 419966437, Deutsche Krebshilfe project number 70113888 (to J.R.V.), Dirección General de Investigación Científica y Técnica, Ministerio de Ciencia e Innovación (RTI2018-094734-B-C21) (to WJ). A special thank is going to the animal care takers of the Central Animal Unit in DKFZ and the Light Microscopy unit of the DKFZ and in particular to Dr. Damir Kronic for his help in image analysis.

Conflict of interest: The authors declare that they have no conflict of interest.

References

- 1 Marcellin P, Kutala BK. Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening. *Liver Int.* 2018. doi:10.1111/liv.13682
- 2 Ramachandran P, Dobie R, Wilson-Kanamori JR, *et al.* Resolving the fibrotic niche of human liver cirrhosis at single-cell level. *Nature* Published Online First: 2019. doi:10.1038/s41586-019-1631-3
- 3 Morales-Ruiz M, Rodríguez-Vita J, Jiménez W, *et al.* Pathophysiology of Portal Hypertension. In: *PanVascular Medicine, Second Edition*. 2015. doi:10.1007/978-3-642-37078-6_141
- 4 Roehlen N, Crouchet E, Baumert TF. Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives. *Cells* Published Online First: 2020. doi:10.3390/cells9040875
- 5 Ruiz-Ortega M, Rodríguez-Vita J, Sanchez-Lopez E, *et al.* TGF-beta signaling in vascular fibrosis. *Cardiovasc Res* 2007;**74**:196–206. doi:10.1016/j.cardiores.2007.02.008
- 6 Glinka Y, Stoilova S, Mohammed N, *et al.* Neuropilin-1 exerts co-receptor function for TGF-beta-1 on the membrane of cancer cells and enhances responses to both latent and active TGF-beta. *Carcinogenesis* 2011;**32**:613–21. doi:10.1093/carcin/bgq281
- 7 Ding Z, Du W, Lei Z, *et al.* Neuropilin 1 modulates TGF- β 1-induced epithelial-mesenchymal transition in non-small cell lung cancer. *Int J Oncol* 2020;**56**:531–43. doi:10.3892/ijo.2019.4938
- 8 Grandclement C, Pallandre JR, Valmary Degano S, *et al.* Neuropilin-2 Expression Promotes TGF- β 1-Mediated Epithelial to Mesenchymal Transition in Colorectal Cancer Cells. *PLoS One* 2011;**6**:e20444. <https://doi.org/10.1371/journal.pone.0020444>
- 9 Kolodkin AL, Matthes DJ, Goodman CS. The semaphorin genes encode a family of transmembrane and secreted growth cone guidance molecules. *Cell* Published Online First: 1993. doi:10.1016/0092-8674(93)90625-Z
- 10 Worzfeld T, Offermanns S. Semaphorins and plexins as therapeutic targets. *Nat Rev Drug Discov* 2014;**13**:603–21. doi:10.1038/nrd4337
- 11 De Minicis S, Rychlicki C, Agostinelli L, *et al.* Semaphorin 7A contributes to TGF- β -mediated liver fibrogenesis. *Am J Pathol* 2013;**183**:820–30.

doi:10.1016/j.ajpath.2013.05.030

- 12 Mecollari V, Nieuwenhuis B, Verhaagen J. A perspective on the role of class III semaphorin signaling in central nervous system trauma. *Front Cell Neurosci* 2014;**8**:1–17. doi:10.3389/fncel.2014.00328
- 13 Jeon KI, Nehrke K, Huxlin KR. Semaphorin 3A potentiates the profibrotic effects of transforming growth factor- β 1 in the cornea. *Biochem Biophys Res Commun* Published Online First: 2020. doi:10.1016/j.bbrc.2019.10.107
- 14 Yagai T, Miyajima A, Tanaka M. Semaphorin 3E secreted by damaged hepatocytes regulates the sinusoidal regeneration and liver fibrosis during liver regeneration. *Am J Pathol* 2014;**184**:2250–9. doi:10.1016/j.ajpath.2014.04.018
- 15 Papic N, Zidovec Lepej S, Gorenc L, *et al.* The association of semaphorins 3C, 5A and 6D with liver fibrosis stage in chronic hepatitis C. *PLoS One* 2018;**13**:e0209481. doi:10.1371/journal.pone.0209481
- 16 Sakurai A, Doçi CL, Gutkind JS. Semaphorin Signaling. 2017;**1493**:163–70. doi:10.1007/978-1-4939-6448-2
- 17 Cao S, Yaqoob U, Das A, *et al.* Neuropilin-1 promotes cirrhosis of the rodent and human liver by enhancing PDGF/TGF-beta signaling in hepatic stellate cells. *J Clin Invest* 2010;**120**:2379–94. doi:10.1172/JCI41203
- 18 Wang L, Feng Y, Xie X, *et al.* Neuropilin-1 aggravates liver cirrhosis by promoting angiogenesis via VEGFR2-dependent PI3K/Akt pathway in hepatic sinusoidal endothelial cells. *EBioMedicine* Published Online First: 2019. doi:10.1016/j.ebiom.2019.04.050
- 19 Feiner L, Webber AL, Brown CB, *et al.* Targeted disruption of semaphorin 3C leads to persistent truncus arteriosus and aortic arch interruption. *Development* 2001;**128**:3061–70.
- 20 Gu C, Rodriguez ER, Reimert D V, *et al.* Neuropilin-1 conveys semaphorin and VEGF signaling during neural and cardiovascular development. *Dev Cell* 2003;**5**:45–57. doi:10.1016/s1534-5807(03)00169-2
- 21 Wang Y, Cao Y, Yamada S, *et al.* Cardiomyopathy and Worsened Ischemic Heart Failure in SM22- α Cre-Mediated Neuropilin-1 Null Mice: Dysregulation of PGC1 α and Mitochondrial Homeostasis. *Arterioscler Thromb Vasc Biol* 2015;**35**:1401–12.

doi:10.1161/ATVBAHA.115.305566

- 22 Borojevic R, Monteiro ANA, Vinhas SA, *et al.* Establishment of a continuous cell line from fibrotic schistosomal granulomas in mice livers. *Vitr Cell Dev Biol* 1985;**21**:382–90.
doi:10.1007/BF02623469
- 23 Mederacke I, Dapito DH, Affò S, *et al.* High-yield and high-purity isolation of hepatic stellate cells from normal and fibrotic mouse livers. *Nat Protoc* 2015;**10**:305–15.
doi:10.1038/nprot.2015.017
- 24 Subramanian A, Tamayo P, Mootha VK, *et al.* Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A* 2005;**102**:15545–50. doi:10.1073/pnas.0506580102
- 25 El Taghdouini A, Najimi M, Sancho-Bru P, *et al.* In vitro reversion of activated primary human hepatic stellate cells. *Fibrogenesis Tissue Repair* 2015;**8**:1–15.
doi:10.1186/s13069-015-0031-z
- 26 McPherson S, Henderson E, Burt AD, *et al.* Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease. *J Hepatol* 2014;**60**:1055–62.
doi:10.1016/j.jhep.2014.01.010
- 27 Mumblat Y, Kessler O, Ilan N, *et al.* Full-length semaphorin-3C is an inhibitor of tumor lymphangiogenesis and metastasis. *Cancer Res* 2015;**75**:2177–86. doi:10.1158/0008-5472.CAN-14-2464
- 28 Cao Y, Szabolcs A, Dutta SK, *et al.* Neuropilin-1 mediates divergent R-smad signaling and the myofibroblast phenotype. *J Biol Chem* Published Online First: 2010.
doi:10.1074/jbc.M110.151696
- 29 Eslam M, Newsome PN, Sarin SK, *et al.* A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. *J Hepatol* 2020;**73**:202–9. doi:<https://doi.org/10.1016/j.jhep.2020.03.039>
- 30 Dewidar B, Meyer C, Dooley S, *et al.* TGF- β in Hepatic Stellate Cell Activation and Liver Fibrogenesis-Updated 2019. *Cells* 2019;**8**:1419. doi:10.3390/cells8111419
- 31 Yang W-J, Hu J, Uemura A, *et al.* Semaphorin-3C signals through Neuropilin-1 and PlexinD1 receptors to inhibit pathological angiogenesis. *EMBO Mol Med* 2015;**7**:1267–84.
doi:10.15252/emmm.201404922

Figure legends

Figure 1. SEMA3C expression is associated with liver fibrosis in humans. **A** GSEA of the dataset GSE45050 using GO_SEMAPHORIN_PLEXIN_SIGNALING_PATHWAY gene set. Left panel shows a heatmap of the 10 genes most differentially enriched with the most enriched gene at the bottom. Right panel shows the enrichment plot including the Normalization Enrichment score (NES) and false discovery rate (FDR). **B-D** GSEA of the dataset GSE61260 (B) GSE103580 (C) GSE83898 (D) using “Cirrhosis signature” gene set obtained from A. Patients were classified according their expression levels of SEMA3C as over (high) or under (low) the mean. Left panels show a heatmap of the 10 genes most differentially enriched with the most enriched gene at the bottom. Right panel shows the enrichment plots including the NES and FDR. **E** Immunohistochemistry for SM22 α (stained by alkaline phosphatase AP) and SEMA3C (stained by DAB) were performed on serial sections of human livers. Samples were counterstained with haematoxylin/eosin. Both proteins were found in perisinusoidal areas and more fibrotic areas (arrows). **F** Similar results were obtained with co-staining of SEMA3C (DAB) and DESMIN (AP). Scale bars are 200 μ m in the zoom-out images and 50 μ m in the zoom-in images.

Figure 2. SEMA3C is upregulated during liver fibrosis in mice. **A** *Sema3C* expression was analysed by qRT-PCR in 3 different models of liver fibrosis: 6 weeks of carbon tetrachloride-treatment (CCl₄, column in red), 24 weeks of fructose-palmitate-cholesterol high fat diet (FPC, column in blue) and 13 weeks of high fat diet (HFD, column in green). Each mouse is denoted as a black dot and the mean \pm SD of each group is represented as a column. White columns represent control mice. Two-tailed non-parametric Mann-Whitney test was performed to evaluate data significance. ** indicates p value <0,01. **B** DAB-SEMA3C staining (in brown) and AP-DESMIN staining (in purple) were performed on control livers and livers with advanced fibrosis (6 weeks CCl₄-treatment). Tissue was counterstained with haematoxylin. Scale bars are 200 μ m in the zoom-out images and 50 μ m in the zoom-in images.

Figure 3. SEMA3C is a marker of hepatic stellate cells (HSC) and exacerbates fibroblast activation. **A** HSCs were isolated from WT mice and one portion was immediately frozen, while the other one was maintained in culture with complete medium for 9 days. Gene expression of *Sema3C* was analysed in these samples by qRT-PCR. Two-tailed paired t-test was performed to evaluate data significance. **B** HSCs were isolated from SM22 α ^{CRE}/SEMA3C^{f/f} mice and the control CRE- littermates, and cultured for 9 days. Gene expression of *Ctgf*, *Tagln* (SM22 α) and

Acta2 (α SMA) was analysed by qRT-PCR. One-tailed non-parametric Mann-Whitney test was performed to evaluate data significance. **C** SEMA3C-overexpressing GRX (SEMA3C, S) and control GRX (empty, E) were stimulated with TGF- β for 3 or 24 hours and gene expression of activation markers was evaluated by qRT-PCR. Given that the experiments were performed on a cell line, Gaussian distribution was assumed and unpaired t-test was used to evaluate data significance. **D** Phosphorylation of SMAD2/3 was evaluated by Western blot, after 15 minutes of activation and VCP was used as loading control. Image is representative of 3 independent experiments. **E** Immunofluorescence of α SMA was performed on 24h-activated GRX. Scale bar is 200 μ m. * and ** correspond to p value <0,05 and <0,01, respectively.

Figure 4. SEMA3C exacerbates liver fibrosis in mice. Liver fibrosis was induced in SM22 α ^{CRE}/SEMA3C^{fl/fl} mice and their control CRE- littermates, by CCl₄-treatment for 6 weeks. **A** SEMA3C staining (by DAB in brown) and DESMIN staining (by AP in purple) were performed to determine fibroblast-specific SEMA3C deletion (arrows) in CRE+ mice. Scale bars are 50 μ m. **B** Gene expression of *Acta2* (α SMA) and *S100a6* was analysed in these samples by qRT-PCR. **C** Liver fibrosis was also evaluated by immunofluorescence of α SMA. Here, one representative image of a liver lobe and its zoom-in are shown for each group. Scale bars are 1000 μ m. **D** α SMA staining was examined and quantified with Fiji Software. **E** The same samples were analysed by Western blot. Fibronectin (FN1), heavy-chain immunoglobulin (hc-Ig), SM22 α and the loading control VCP are here shown and the bands quantified (**F**). One-tailed non-parametric Mann-Whitney test was performed to evaluate data significance in the experiments of this figure. * and ** correspond to p value <0,05 and <0,01, respectively.

Figure 5. NRP2 on activated fibroblasts mediates fibrosis in mice. **A** Western blot was performed on whole liver tissues of mice treated for 2, 4 and 6 weeks (w) with CCl₄ and their control littermates. Blots of Neuropilin-1 (NRP1), Neuropilin-2 (NRP2) and VCP are shown. **B** Gene expression of *Nrp1*, *Plxnd1* and *Nrp2* was analysed by qRT-PCR in freshly-isolated WT-HSCs and after 9 days of culture. Since it could not be predicted in which direction to expect a difference, two-tailed paired t-test was performed to evaluate data significance. **C** HSCs from SM22 α ^{CRE}/NRP2^{fl/fl} mice and the control CRE- littermates were cultured for 9 days and gene expression of *Ctgf*, *Tagln* (SM22 α) and *Acta2* (α SMA) was examined by qRT-PCR. **D** Liver fibrosis was induced in SM22 α ^{CRE}/NRP2^{fl/fl} mice and the control CRE- littermates by CCl₄-treatment for 6 weeks. Liver fibrosis was evaluated by immunofluorescence of α SMA. Representative images of livers are shown for each group. Scale bars are 1000 μ m. **E** α SMA

staining was analysed and quantified with Fiji software. **F** The same samples were also investigated by Western blot. FN1, hc-Ig and SM22 α were used as markers for liver fibrosis and NRP2 was detected to verify knock-out of NRP2. **G** Bands were quantified and normalised to VCP. One-tailed non-parametric Mann-Whitney test was performed to evaluate the significance of data in this figure, with the exception of data in panel B. *, ** and *** correspond to p value <0,05, <0,01 and <0,001 respectively.











Figure 1





A*Sema3C**Sema3C**Sema3C*







bioRxiv preprint doi: <https://doi.org/10.1101/2021.07.29.454292>; this version posted July 29, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).







**B**

SEMA3C - DESMIN





A**B****C****D****E****F**

A**B****C****D****E****F****G**